Cat . Non | Espèces | Description du produit | Structure | Pureté | Caractéristique |
---|---|---|---|---|---|
SCRAJ-STT204 | Human | Raji/Membrane-Bound Human TL1A Stable Cell Line Development Service | |||
CHEK-ATP198 | Human | HEK293/Membrane-Bound human TL1A Stable Cell Line | |||
TLA-H5246 | Human | Human TL1A / TNFSF15 Protein, His Tag (Monomer) (MALS verified) | ![]() |
![]() ![]() |
|
CHEK-ATP142 | Human | HEK293/Human TL1A Stable Cell Line | |||
TLA-R5249 | Rat | Rat TL1A Protein, His Tag | ![]() |
![]() ![]() |
|
TLA-H5245 | Human | Human TL1A / TNFSF15 Protein, His Tag | ![]() |
![]() ![]() |
|
TLA-M5243 | Mouse | Mouse TL1A Protein, His Tag (HPLC-verified) | ![]() |
![]() ![]() ![]() ![]() |
|
TLA-H5244 | Human | Human TL1A / TNFSF15 Protein, His Tag (MALS verified) | ![]() |
![]() ![]() |
|
TLA-H52Q1 | Human | Biotinylated Human TL1A / TNFSF15 Protein, His,Avitag™ | ![]() |
![]() ![]() |
|
TLA-C5241 | Cynomolgus / Rhesus macaque | Cynomolgus/Rhesus macaque TL1A / TNFSF15 Protein, His Tag | ![]() |
![]() ![]() |
|
TLA-H5243 | Human | Human TL1A / TNFSF15 Protein, His Tag, active trimer (MALS verified) | ![]() |
![]() ![]() |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
RG-6631 | RG6631; RG-6631 | Phase 3 Clinical | F. Hoffmann-La Roche Ltd | Colitis, Ulcerative | Details |
Tulisokibart | PRA-023; MK-7240; PRA023 | Phase 3 Clinical | Prometheus Biosciences Inc, Merck Sharp & Dohme LLC | Inflammatory Bowel Diseases; Lung Diseases, Interstitial; Colitis, Ulcerative; Scleroderma, Diffuse; Crohn Disease | Details |
Duvakitug | TEV574; TEV-574; TEV-48574; TEV-574; TEV574; SAR447189; SAR-447189 | Phase 2 Clinical | Teva Pharmaceutical Industries Ltd | Asthma; Colitis, Ulcerative; Crohn Disease | Details |
XmAb-942 | XmAb942; XmAb-942 | Phase 2 Clinical | Xencor Inc | Inflammatory Bowel Diseases; Colitis, Ulcerative | Details |
RVT-3101 | PF-06480605; PF 6480605; RVT-3101 | Phase 2 Clinical | Pfizer Inc | Inflammatory Bowel Diseases; Colitis, Ulcerative; Crohn Disease | Details |
PF-07261271 | PF-07261271 | Phase 1 Clinical | Pfizer Inc | Inflammatory Bowel Diseases | Details |
SPY-002 | SPY002-091; SPY002 072; SPY-002; PR-010 | Phase 1 Clinical | Paragon Therapeutics Inc | Details | |
SPY002-072 | SPY002-072 | Phase 1 Clinical | Spyre Therapeutics Inc, Novotech (Australia) Pty Ltd | Details | |
BCD-261 | BCD-261 | Phase 1 Clinical | BIOCAD JSC | Colitis, Ulcerative; Crohn Disease | Details |
Next-generation anti-TL1A antibody(Telavant) | Phase 1 Clinical | Telavant Inc | Fibrosis; Inflammation | Details |
This web search service is supported by Google Inc.